Dr. Rahul A. Parikh, MD, PHD
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 25
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 336
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
KS license 04-40535 -
Hematology & Oncology Physician
KS license 04-40535 · PA license MD445914 -
Internal Medicine Physician
PA license MT189101
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Kansas Hospital Kansas City, KS
- University of Kansas Health System Olathe Hospital Olathe, KS
- Freeman Health System - Freeman West Joplin, MO
- University of Kansas Health System - St Francis Campus Topeka, KS
- Miami County Medical Center Paola, KS
Medical groups
- University of Kansas Hospital Authority (250 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 336
- Services billed
- 1,415
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 596 | 262 |
| Established patient office or other outpatient visit, 40-54 minutes | 386 | 158 |
| Established patient office or other outpatient visit, 20-29 minutes | 83 | 68 |
| New patient office or other outpatient visit, 45-59 minutes | 27 | 27 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 26 | 26 |
| New patient office or other outpatient visit, 60-74 minutes | 25 | 25 |
| Telephone medical discussion with physician, 21-30 minutes | 24 | 20 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 20 | 20 |
| New patient office or other outpatient visit, 30-44 minutes | 17 | 17 |
| Telephone medical discussion with physician, 11-20 minutes | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisone Other prescribers in Westwood, KS | 119 |
| Ondansetron Hcl Other prescribers in Westwood, KS | 106 |
| Cabometyx (cabozantinib s-malate) | 100 |
| Abiraterone Acetate | 93 |
| Levothyroxine Sodium Other prescribers in Westwood, KS | 61 |
| Orgovyx (relugolix) | 55 |
| Xtandi (enzalutamide) | 47 |
| Morphine Sulfate Er (morphine sulfate) Other prescribers in Westwood, KS | 46 |
| Amlodipine Besylate Other prescribers in Westwood, KS | 45 |
| Dexamethasone Other prescribers in Westwood, KS | 43 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $26.00 in total to this clinician.
| Pfizer Inc. | $26.00 |
|---|
| Education | $26.00 |
|---|
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Pfizer Inc. Apr 10, 2025 | Education PADCEV · ONCOLOGY · in-kind | $26.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 4 companies. The companies reported $528,443 in research payments for these studies, mostly to the institutions running them.
- A phase 3 randomized doubleblind placebocontrolled study of talazoparib with enzalutamide in metastatic castrationresistant prostate cancer
Pfizer Inc. - A Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with High-Risk, Metastatic Castration-Resistant Prostate Cancer
Exelixis Inc. - A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors
Exelixis Inc. - A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment Followed by Durvalumab Alone for A…
AstraZeneca Pharmaceuticals LP - A Phase III Randomized Open-Label Controlled Multi-Center Global Study of First-Line Durvalumab in Combination with Standard of Care Chemotherapy and Durvalumab in Combination with Tremelimumab and Standard of Care Ch…
AstraZeneca Pharmaceuticals LP - A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
Astellas Pharma Global Development
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.